Full-Time

Manager – Quality Systems and Compliance

Posted on 6/11/2025

Deadline 6/15/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$98.4k - $119.3k/yr

+ Incentive Cash + Stock Opportunities

Senior

Company Historically Provides H1B Sponsorship

Summit, NJ, USA + 1 more

More locations: Franklin Township, NJ, USA

This position requires up to 10% of travel.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Strong collaborative skills
  • Effective written and verbal communication
  • Computer literacy: Microsoft Office and other systems as required
  • Addresses each event timely and properly and provides insight into potential business disruptions.
  • Prioritizes when handling multiple work assignments and deadlines.
  • Provides clear direction and priorities.
  • Bachelor’s degree is required
  • 5+ years of relevant quality experience in the life sciences industry is required
  • Demonstrated proficiency in interpretation of FDA and EMA cGMP regulations as they apply to clinical supplies
  • Demonstrated interpersonal, communication, and motivation skills.
  • Experience within a QA environment is required
Responsibilities
  • Manages and maintains administrative oversight of PD Quality Agreements, facilitating the creation and filing of new quality agreements in the document management system in addition to supporting periodic revision of existing quality agreements.
  • Owns the local execution of the Deviation Monitoring and Deviation Evaluation programs; analyzes deviations across PD sites to identify trends and deficiencies and works with the sites to develop remedial actions as necessary.
  • Authors, reviews and approves documentation. Monitors documentation activities performed in document management system. Supports and coordinates document periodic revisions as required within Product Development Quality.
  • Supports the Document Management program by driving on-time completion of periodic document reviews, providing compliance and system support for PD/PDQ stakeholders, and general management of the QMS including daily maintenance, integrations, and go-live implementations.
  • Supports the Management Review process through the collection, documentation, and reporting of PD metrics.
  • Provides support for the PD Self-Inspection program by functioning as a support auditor when necessary.
  • Provides support for all remaining PDQ QS&C functions where necessary, including Complaint Management, Quality Risk Management, Records Management, and Training Management.
  • Supports quality harmonization and integration efforts across PD sites.
  • Provides support for regulatory inspections/audits and internal audits, ensuring successful inspection readiness activities and compliance with health authority requirements.
  • Build and foster strong relationships with stakeholders to meet the demands of a changing matrixed environment.
  • Adheres to BMS core behaviors.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are then sold after receiving regulatory approval. BMS also produces generic drugs, providing affordable alternatives that maintain the same quality and safety as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by making effective treatments accessible while adhering to high standards of environmental and social governance.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with BioNTech enhances BMS's oncology portfolio against competitors like Merck.
  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • $40 billion US investment shows BMS's commitment to long-term growth and innovation.

What critics are saying

  • Heavy reliance on real-world data may affect drug approval if data quality falters.
  • $11.1 billion BioNTech partnership could strain finances if results are underwhelming.
  • Recent layoffs may impact operational efficiency and employee morale at BMS.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company integrates real-world data to enhance drug development and patient outcomes.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

Hit Consultant
Jun 10th, 2025
From Raw Records To Real-Time Insights: Climbing Pharma’S Real-World Data Maturity Curve

Viraj Narayanan, CEO at Cornerstone AI Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers SquibbReal-world data (RWD) has become the pharmaceutical industry’s most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and repeatable approach to data quality, as well as a strategic roadmap that moves an organization from minimal use of RWD to a position of true leadership. This journey isn’t simple, but for those committed to navigating it, the competitive advantages are substantial. And, importantly, RWD holds the potential to help bring lifesaving and life-changing medications to market faster and safer than ever before.From Data Collection to MaturityPharma’s growing reliance on RWD has encouraged an influx of partnerships with data aggregators, medical institutions, and digital health platforms. Yet, not all companies are at the same level of maturity in using that data effectively

Devdiscourse
Jun 2nd, 2025
Reuters Health News Summary

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

The Motley Fool
Jun 2nd, 2025
Why BioNTech Stock Soared Today

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327.

INACTIVE